Incyte To Acquire ARIAD's European Operations, In-license Iclusig In Europe

(RTTNews) - Incyte and ARIAD Pharmaceuticals, Inc. (ARIA) announced an agreement for Incyte to acquire ARIAD's European operations for $140 million. The companies will also enter into a license agreement whereby Incyte will obtain an exclusive license to develop and commercialize Iclusig (ponatinib) in Europe and other select countries. Incyte expects the transaction to be earnings accretive in 2018.

Iclusig is approved in Europe for the treatment of patients with chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia who are resistant to or intolerant of certain second generation BCR-ABL inhibitors and all patients who have the T315I mutation.